Image-guided Stereotactic Body Radiotherapy (SBRT) for prostate cancer
Lay Title: MIRAGE Protocol for Prostate Cancer
Technical Title: Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy For Prostate Cancer (MIRAGE): A Phase III Randomized Trial
Disease Type: Adenocarcinoma of the prostate
Basic information: Image-guided Stereotactic Body Radiotherapy (SBRT) is a standard treatment for your type of prostate cancer. This treatment combines imaging of the cancer within the body, with the delivery of therapeutic radiation doses produced on a linear accelerator machine. Imaging modalities for image-guided SBRT can be either Computed Tomography (CT), Magnetic Resonance (MR or MRI), or a combination of the two. This research is being done to help determine whether there are benefits to MRI-guidance over CT-guidance in those who are receiving the same radiation dose by SBRT.
Research Procedures (not a complete list): If you agree to participate in this study, you will receive the same therapeutic radiation dose that you otherwise would, but you will first be randomly assigned to one of two groups. The first of these groups will receive SBRT that is guided by Computed Tomography (CT) imaging alone. The second of the groups will receive SBRT that is guided by Magnetic Resonance (MR or MRI) imaging alone.
Participation in this research may require an additional five (5) minutes during your treatment follow-up visits to complete study questionnaires. If you agree to participate in this study, you will undergo radiation therapy as a part of routine care. You will also complete routine medical blood tests and an optional mouth swab.
You will return for routine follow-up visits be around one month after radiotherapy is completed and then around every 3 months post-radiation therapy. These follow-up visits and their frequency are routine. They may include a routine physical exam, routine questionnaires about your quality of life, and routine blood collection for medical tests.
Eligibility Criteria (not a complete list):
For More Detailed Information, Contact: